Record revenue of $12.3 million, increased 22% year over year
Progress on four success pillars, including 54% of revenue from recurring patient sources
Narrowing full-year revenue guidance to $46-47 million, at the
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
OrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Revenue of $11.7 million, increased 21% year over year
Four success pillars driving higher revenue growth and operating leverage
Raising full year revenue guidance to $45-47 million
Conference call begins at 4:30pm
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today
Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources
MyoPro® orders received during the quarter were up 12% year-over-year
Expanded gross margin, lower operating expenses
Myomo, Inc. (NYSE:MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro device through Ottobock Care clinics nationwide.
Ottobock
Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that
Myomo, Inc. (NYSE:MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new
